Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 276 to 300 of 335

Guidance and quality standards awaiting development
Title	Type
STS101 for treating acute migraine TS ID 11782	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977	Technology appraisal guidance
Supporting independent living and preventing isolation in adults of working age with social care needs	Quality standard
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460	Technology appraisal guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance
Thyroid disease	Quality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tinnitus	Quality standard
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217	Technology appraisal guidance
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683	Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance

Results per page

10
25
50
All